SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway-Reference-Cited by-同舟云学术

SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway

Published:2020-01-03 Issue: Volume: Page:
ISSN:1791-2997
Container-title:Molecular Medicine Reports
language:
Short-container-title:Mol Med Report

Author:

Ding Jun¹,Qin Daming²,Zhang Yong¹,Li Qinghe¹,Li Yi¹,Li Jinmao¹

Affiliation:

1. Department of Hepatobiliary Surgery, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture (Enshi Clinical College of Wuhan University), Enshi, Hubei 445000, P.R. China

2. Department of Radiology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture (Enshi Clinical College of Wuhan University), Enshi, Hubei 445000, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,Genetics,Molecular Biology,Molecular Medicine,Biochemistry

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extracellular Vesicle (EV) Survivin for Cancer Diagnostics and Therapeutics: A Review;Frontiers in Bioscience-Landmark;2024-08-22

2. NAP1L1 regulates BIRC2 ubiquitination modification via E3 ubiquitin ligase UBR4 and hence determines hepatocellular carcinoma progression;Cell Death Discovery;2024-03-27

3. Birinapant Reshapes the Tumor Immunopeptidome and Enhances Antigen Presentation;International Journal of Molecular Sciences;2024-03-25

4. OTU deubiquitinase 7B facilitates the hyperthermia‐induced inhibition of lung cancer progression through enhancing Smac‐mediated mitochondrial dysfunction;Environmental Toxicology;2023-12-13

5. Targeting survivin for cancer therapy: Strategies, small molecule inhibitors and vaccine based therapeutics in development;Life Sciences;2023-12